BioCryst Pharmaceuticals (BCRX) Projected to Post Earnings on Wednesday

Key Points

• BioCryst (NASDAQ: BCRX) is scheduled to report Q1 2026 results before the open on May 6, 2026 (8:30 AM ET), with analysts forecasting $0.07 EPS and $151.66M in revenue.
• In the prior quarter (reported Feb. 26), BioCryst beat expectations with $1.12 EPS and $163.28M revenue, a year‑over‑year revenue increase of 209.1%.
• The stock carries a consensus rating of “Moderate Buy” (ten Buys, three Holds) with an average price target of $19.64, while insider Alane P. Barnes recently sold 150,000 shares.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) will likely be releasing its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect BioCryst Pharmaceuticals to post earnings of $0.07 per share and revenue of $151.6630 million for the quarter. Interested persons may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:30 AM ET.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The biotechnology company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.07 by $1.05. BioCryst Pharmaceuticals had a net margin of 30.16% and a negative return on equity of 84.33%. The business had revenue of $163.28 million for the quarter, compared to analysts' expectations of $151.32 million. During the same period in the prior year, the firm earned ($0.13) earnings per share. BioCryst Pharmaceuticals's revenue was up 209.1% compared to the same quarter last year. On average, analysts expect BioCryst Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

BioCryst Pharmaceuticals Price Performance

BCRX opened at $8.86 on Wednesday. BioCryst Pharmaceuticals has a one year low of $6.00 and a one year high of $11.31. The company's 50 day simple moving average is $8.93 and its 200-day simple moving average is $7.75. The stock has a market capitalization of $2.25 billion, a P/E ratio of 7.38 and a beta of 0.70.

Analysts Set New Price Targets

BCRX has been the topic of several analyst reports. Weiss Ratings upgraded shares of BioCryst Pharmaceuticals from a "sell (d-)" rating to a "hold (c)" rating in a report on Wednesday, March 4th. Royal Bank Of Canada cut their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an "outperform" rating on the stock in a report on Friday, January 30th. Finally, Evercore initiated coverage on shares of BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They issued an "outperform" rating and a $17.00 price objective on the stock. Ten research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, BioCryst Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $19.64.

Insiders Place Their Bets

In related news, insider Alane P. Barnes sold 150,000 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $9.15, for a total value of $1,372,500.00. Following the transaction, the insider directly owned 400,703 shares in the company, valued at $3,666,432.45. This represents a 27.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 5.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several large investors have recently bought and sold shares of BCRX. Quarry LP acquired a new stake in BioCryst Pharmaceuticals in the fourth quarter worth $234,000. Captrust Financial Advisors raised its holdings in BioCryst Pharmaceuticals by 7.4% in the second quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company's stock worth $198,000 after purchasing an additional 1,527 shares during the period. Tower Research Capital LLC TRC raised its holdings in BioCryst Pharmaceuticals by 213.7% in the second quarter. Tower Research Capital LLC TRC now owns 21,758 shares of the biotechnology company's stock worth $195,000 after purchasing an additional 14,822 shares during the period. Abel Hall LLC acquired a new stake in BioCryst Pharmaceuticals in the fourth quarter worth $194,000. Finally, LPL Financial LLC raised its holdings in BioCryst Pharmaceuticals by 43.9% in the fourth quarter. LPL Financial LLC now owns 24,480 shares of the biotechnology company's stock worth $191,000 after purchasing an additional 7,467 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.